METABOLIC DISORDERS
Osteoporosis: Weekly 28.2ug teriparatide reduces vertebral fracture risk
This report has been verified
by one or more authors of the
original publication.
Calcif Tissue Int. 2014 Feb;94(2):170-5. doi: 10.1007/s00223-013-9777-8. Epub 2013 Aug 21
316 primary osteoporosis patients were randomized to receive a 28.2ug injection of teriparatide or placebo injection (1.4ug teriparatide) once-weekly for 3 years, to determine the effects of teriparatide on vertebral fracture prevention and lumbar spine BMD. Results indicated that teriparatide reduced the risk of vertebral fractures and increased lumbar bone mineral density compared to placebo, but it also resulted in higher total adverse drug reactions.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
